PressNovember 6, 2023 Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
PressNovember 6, 2023 Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
PressNovember 6, 2023 DEA Announces Major Increase to 2023 Production Quotas for Psilocybin, THC and Ibogaine
PressNovember 6, 2023 Red Light Holland Engages Dr. Taras Nahirny, as Advisor to Help with Distribution of Company Homogenized Psilocybin Microdosing Capsules
PressNovember 3, 2023 Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
PressNovember 3, 2023 Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
PressNovember 2, 2023 Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000
PressNovember 2, 2023 Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
PressNovember 1, 2023 Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
PressOctober 26, 2023 Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
PressOctober 26, 2023 Safe Supply Streaming Co. Ltd. Announces Appointment of Ronan Levy as President
PressOctober 25, 2023 ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy
PressOctober 25, 2023 First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)
PressOctober 25, 2023 The Healing Company’s Chopra and Swan Hellenic Announce Exclusive, Multi-Year Partnership With Launch of Well-Being Travel Experience “Explore & Restore”
PressOctober 25, 2023 Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
PressOctober 23, 2023 FSD Pharma Inc. Announces Filing in Connection with Proposed Arrangement with Celly Nu
PressOctober 23, 2023 Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
